Literature DB >> 18708670

Mechanisms of lymphocyte loss in SARS coronavirus infection.

P K S Chan1, G G Chen.   

Abstract

1. Human lymphocytes and monocytes are not permissive to productive SARS coronavirus (SARS-CoV) infection in vitro. 2. Challenge of lymphocytes and monocytes with infectious SARS-CoV, inactivated virions, and receptor-binding fragment of spike protein does not trigger apoptosis. 3. Direct infection/interaction between viruses and lymphocytes/monocytes is unlikely to be the cause of lymphopaenia in SARS patients. 4. Lymphopaenia in SARS patients is likely to result from indirect mechanisms secondary to the viral infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18708670

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  16 in total

1.  Genotypic characterization of canine coronaviruses associated with fatal canine neonatal enteritis in the United States.

Authors:  Beth N Licitra; Gary R Whittaker; Edward J Dubovi; Gerald E Duhamel
Journal:  J Clin Microbiol       Date:  2014-09-24       Impact factor: 5.948

Review 2.  COVID-19: The Emerging Immunopathological Determinants for Recovery or Death.

Authors:  Tanveer Ahmad; Rituparna Chaudhuri; Mohan C Joshi; Ahmad Almatroudi; Arshad Husain Rahmani; Syed Mansoor Ali
Journal:  Front Microbiol       Date:  2020-12-01       Impact factor: 5.640

3.  Usefulness of monocyte distribution width and presepsin for early assessment of disease severity in COVID-19 patients.

Authors:  Sei Won Kim; Heayon Lee; Sang Haak Lee; Sung Jin Jo; Jehoon Lee; Jihyang Lim
Journal:  Medicine (Baltimore)       Date:  2022-07-08       Impact factor: 1.817

Review 4.  Coronavirus Disease of 2019: a Mimicker of Dengue Infection?

Authors:  Joshua Henrina; Iwan Cahyo Santosa Putra; Sherly Lawrensia; Quinta Febryani Handoyono; Alius Cahyadi
Journal:  SN Compr Clin Med       Date:  2020-07-13

5.  Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial.

Authors:  Huijie Bian; Zhao-Hui Zheng; Ding Wei; Aidong Wen; Zheng Zhang; Jian-Qi Lian; Wen-Zhen Kang; Chun-Qiu Hao; Jing Wang; Rong-Hua Xie; Ke Dong; Jie-Lai Xia; Jin-Lin Miao; Wen Kang; Guoquan Li; Di Zhang; Mingru Zhang; Xiu-Xuan Sun; Likun Ding; Kui Zhang; Junfeng Jia; Jin Ding; Zhiqin Li; Yanyan Jia; Lin-Na Liu; Zhe Zhang; Zhao-Wei Gao; Hong Du; Na Yao; Qing Wang; Ke Wang; Jie-Jie Geng; Bin Wang; Ting Guo; Ruo Chen; Yu-Meng Zhu; Li-Juan Wang; Qian He; Rui-Rui Yao; Ying Shi; Xiang-Min Yang; Jian-Sheng Zhou; Yi-Nan Ma; Ya-Tao Wang; Xue Liang; Fei Huo; Zhe Wang; Yang Zhang; Xu Yang; Ye Zhang; Lu-Hua Gao; Ling Wang; Xiao-Chun Chen; Hao Tang; Shuang-Shuang Liu; Qing-Yi Wang; Zhi-Nan Chen; Ping Zhu
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

6.  Dynamic changes of lymphocyte counts in adult patients with severe pandemic H1N1 influenza A.

Authors:  Yandong Cheng; Hong Zhao; Peixin Song; Zhaoping Zhang; Junhao Chen; Yi-Hua Zhou
Journal:  J Infect Public Health       Date:  2019-06-13       Impact factor: 3.718

Review 7.  A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic.

Authors:  Aishwarya Gulati; Corbin Pomeranz; Zahra Qamar; Stephanie Thomas; Daniel Frisch; Gautam George; Ross Summer; Joseph DeSimone; Baskaran Sundaram
Journal:  Am J Med Sci       Date:  2020-05-11       Impact factor: 2.378

8.  Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.

Authors:  H Hou; B Zhang; H Huang; Y Luo; S Wu; G Tang; W Liu; L Mao; L Mao; F Wang; Z Sun
Journal:  Clin Exp Immunol       Date:  2020-05-15       Impact factor: 4.330

9.  Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.

Authors:  Yunjeong Kim; Hongwei Liu; Anushka C Galasiti Kankanamalage; Sahani Weerasekara; Duy H Hua; William C Groutas; Kyeong-Ok Chang; Niels C Pedersen
Journal:  PLoS Pathog       Date:  2016-03-30       Impact factor: 6.823

Review 10.  Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action.

Authors:  Somaye Sadeghi; Sara Soudi; Abbas Shafiee; Seyed Mahmoud Hashemi
Journal:  Life Sci       Date:  2020-09-23       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.